Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SGN-TGT |
Synonyms | |
Therapy Description |
SGN-TGT is a nonfucosylated monoclonal antibody that targets TIGIT, thereby preventing its interaction with CD112 and CD155 and enhancing the interaction of CD112 and CD155 with CD226 expressed on immune cells, which may lead to activation of an anti-tumor immune response (NCI Drug Dictionary, Cancer Res (2023) 83 (8_Supplement): CT265). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGN-TGT | SGN TGT|SEA-TGT|SGNTGT | TIGIT Antibody 19 | SGN-TGT is a nonfucosylated monoclonal antibody that targets TIGIT, thereby preventing its interaction with CD112 and CD155 and enhancing the interaction of CD112 and CD155 with CD226 expressed on immune cells, which may lead to activation of an anti-tumor immune response (NCI Drug Dictionary, Cancer Res (2023) 83 (8_Supplement): CT265). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04254107 | Phase I | SGN-TGT Pembrolizumab + SGN-TGT | A Safety Study of SGN-TGT in Patients With Advanced Cancer | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |